Suzhou Puhe Biopharma Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, diabetes, obesity, heart failure, hypertension, pulmonary hypertension, sarcopenia and scleroderma.

Chong Kun Dang Pharmaceutical Corp. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of fibrosis, neurodegeneration, nutrition, endocrine, immunological, inflammatory, psychiatric and renal disorders, among others.

Barth syndrome is a rare genetic disorder caused by mutations in the TAZ gene, which encodes an enzyme essential for remodeling cardiolipin, critical for mitochondrial function. A recent study published in Nature identified the enzyme ABHD18 as a candidate deacylase in the cardiolipin biosynthesis pathway and a potential therapeutic target for this syndrome.